Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal doxorubicin + CapOX + bevacizumab for first-line SMAD4 R361H/C-mutant advanced colorectal adenocarcinoma
ChiCTR2400087648Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, capecitabine, oxaliplatin and bevacizumab in colorectal adenocarcinoma, sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: Progression-free survival and Objective response rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
pegylated liposomal doxorubicincapecitabineoxaliplatinbevacizumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400087648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087648.